Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:theophylline
|
| gptkbp:activities |
H2 receptor antagonist
|
| gptkbp:approves |
gptkb:1979
|
| gptkbp:brand |
gptkb:Tagamet
|
| gptkbp:clinical_trial |
Phase IV
maintenance therapy for duodenal ulcers short-term treatment of active duodenal ulcers treatment of benign gastric ulcers treatment of erosive esophagitis |
| gptkbp:contraindication |
liver disease
renal impairment |
| gptkbp:discovered_by |
gptkb:Smith_Kline_&_French_Laboratories
|
| gptkbp:dosage_form |
300 mg three times a day
400 mg twice a day 600 mg once a day 800 mg at bedtime |
| gptkbp:duration |
up to 8 weeks
long-term use possible |
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
cimetidine
|
| gptkbp:ingredients |
C10 H16 N6 S
|
| gptkbp:interacts_with |
gptkb:phenytoin
gptkb:theophylline gptkb:warfarin benzodiazepines |
| gptkbp:invention |
gptkb:1997
|
| gptkbp:is_atype_of |
A02 B A01
|
| gptkbp:is_available_on |
gptkb:product
gptkb:tablet injection |
| gptkbp:is_used_for |
treating gastroesophageal reflux disease (GERD)
preventing stomach ulcers treating Zollinger-Ellison syndrome treating ulcers |
| gptkbp:manager |
oral
intravenous |
| gptkbp:marketed_as |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:metabolism |
liver
|
| gptkbp:previous_name |
gptkb:battle
|
| gptkbp:safety_features |
Category B
|
| gptkbp:side_effect |
dizziness
headache nausea confusion diarrhea rash thrombocytopenia gynecomastia elevated liver enzymes impotence |
| gptkbp:type_of |
51481-61-9
|